JP2025509343A - 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用 - Google Patents

多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用 Download PDF

Info

Publication number
JP2025509343A
JP2025509343A JP2024553571A JP2024553571A JP2025509343A JP 2025509343 A JP2025509343 A JP 2025509343A JP 2024553571 A JP2024553571 A JP 2024553571A JP 2024553571 A JP2024553571 A JP 2024553571A JP 2025509343 A JP2025509343 A JP 2025509343A
Authority
JP
Japan
Prior art keywords
antibody
analog
administered
cells
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509343A5 (enExample
Inventor
マリエル・シロン・ブロンデル
アレクサンドル・デジョンケール
ザンドラ・カリーナ・クリペル
マルコ・メローニ
アンジェラ・ヴィロン－オッドス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2025509343A publication Critical patent/JP2025509343A/ja
Publication of JP2025509343A5 publication Critical patent/JP2025509343A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024553571A 2022-03-07 2023-03-07 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用 Pending JP2025509343A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317253P 2022-03-07 2022-03-07
US63/317,253 2022-03-07
PCT/US2023/063869 WO2023172917A1 (en) 2022-03-07 2023-03-07 Use of isatuximab in combination with other agents for the treatment of multiple myeloma

Publications (2)

Publication Number Publication Date
JP2025509343A true JP2025509343A (ja) 2025-04-11
JP2025509343A5 JP2025509343A5 (enExample) 2026-03-16

Family

ID=85800365

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553571A Pending JP2025509343A (ja) 2022-03-07 2023-03-07 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用

Country Status (10)

Country Link
US (1) US20250177519A1 (enExample)
EP (1) EP4489766A1 (enExample)
JP (1) JP2025509343A (enExample)
KR (1) KR20250029015A (enExample)
CN (1) CN119486744A (enExample)
AU (1) AU2023231217A1 (enExample)
CA (1) CA3245572A1 (enExample)
IL (1) IL315471A (enExample)
MX (1) MX2024010925A (enExample)
WO (1) WO2023172917A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3154581B1 (en) * 2014-06-16 2019-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
US11221328B2 (en) * 2017-03-08 2022-01-11 Nantcell, Inc. Hypoxic NK cells and methods therefor
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
CN114867485A (zh) 2019-10-31 2022-08-05 全国儿童医院研究所 Cd38敲除的原代和扩增的人nk细胞的生成
PH12023550160A1 (en) * 2020-07-31 2023-09-18 Exelixis Inc Combinations for the Treatment of Cancer

Also Published As

Publication number Publication date
KR20250029015A (ko) 2025-03-04
EP4489766A1 (en) 2025-01-15
CA3245572A1 (en) 2023-09-14
AU2023231217A1 (en) 2024-10-17
CN119486744A (zh) 2025-02-18
US20250177519A1 (en) 2025-06-05
MX2024010925A (es) 2025-02-10
WO2023172917A1 (en) 2023-09-14
IL315471A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
JP6611709B2 (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用
US20240190984A1 (en) Methods of treating multiple myeloma
CN113710256A (zh) 使用过继细胞疗法的治疗方法
RS64588B1 (sr) Kombinacija anti-pd-1 antitela i bispecifičnih anti-cd20/anti-cd3 antitela za lečenje kancera
RU2662933C2 (ru) Антитела против cd26 и их применение
BR112021007227A2 (pt) método para fornecer administração subcutânea de anticorpos anti-cd38
KR20250029015A (ko) 다발성 골수종의 치료를 위한, 다른 제제와 조합된 이사툭시맙의 용도
TW202328196A (zh) 使用vista抗原結合分子的癌症之治療及預防
JP2025138745A (ja) 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
JP2022028075A (ja) 免疫寛容を誘導する抗体、誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤治療法
US20150368362A1 (en) Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CA3048198A1 (en) Methods of treating multiple myeloma
RU2858309C2 (ru) Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы
RU2838203C2 (ru) Способы лечения множественной миеломы
WO2026033458A1 (en) DOSES AND PHARMACEUTICAL COMPOSITIONS OF A CD33 X Vδ2 BISPECIFIC ANTIBODY FOR THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260306